Orchid Pharma Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

The Orchid Pharma Q2 results FY27 announcement is the next scheduled earnings event for Orchid Pharma Ltd., a maker of antibiotic active pharmaceutical ingredients, principally cephalosporins, along with finished formulations and a novel beta lactamase inhibitor programme, operating plants in Tamil Nadu and supplying regulated and emerging markets. The stock traded at Rs 1,000.20 on the NSE on 15 September 2026, down 0.28% from the previous close of Rs 1,003.05, about 11.7% below its 52-week high of Rs 1,133.00 and 108.4% above its 52-week low of Rs 480.00.

What makes the Orchid Pharma Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 193.52 crore of revenue and a loss of Rs 5.72 crore, while the most recent quarter on record, Q1 FY27, produced Rs 304.17 crore and a profit of Rs 3.22 crore. Everything below is built from those reported figures rather than from any forecast.

Click Here – Get Free Investment Predictions

When Is the Orchid Pharma Q2 Results FY27 Date?

The Orchid Pharma Q2 results date for FY27 is not confirmed. As of 15 September 2026, Orchid Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.

What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Orchid Pharma Q2 results date becomes public through that filing rather than through any advance announcement.

The Orchid Pharma Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Orchid Pharma.

Orchid Pharma Q2 Results Expectations: What the Market Is Actually Tracking

No verified analyst estimate for the Orchid Pharma Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Orchid Pharma. The Orchid Pharma Q2 results watchlist below is built from what the company has actually reported and disclosed.

The first is revenue, which was Rs 193.52 crore in September 2025 against Rs 304.17 crore in Q1 FY27, a rise of about 57%. September 2025 was the smallest quarter of the five, and the series peaked at Rs 368.33 crore in March 2026.

The second is the operating margin, which was negative 0.76% in September 2025 and positive 4.60% in Q1 FY27. The first two quarters of the window were operating losses, and the margin has been positive in the three quarters since, peaking at 8.19% in March 2026.

The third is the tax line, which is nil. The effective rate was 0.00% in four of the five quarters and 2.64% in the fifth, so March 2026 passed Rs 24.85 crore of pre tax profit through almost untouched to Rs 25.84 crore, against roughly Rs 18.64 crore at a normal rate.

Check Orchid Pharma Ltd. Live Fundamentals on the Univest Screener

Orchid Pharma Q2 Results Preview: The Q1 FY27 Actuals It Builds On

Orchid Pharma Ltd. reported revenue of Rs 304.17 crore in Q1 FY27, up 15.57% from Rs 263.19 crore in Q1 FY26, and a profit of Rs 3.22 crore at the net level, a swing from a loss of Rs 5.69 crore in Q1 FY26 to a profit of Rs 3.22 crore. These are reported actuals, not estimates.

Sequentially, revenue was down 17.42% over the March 2026 quarter figure of Rs 368.33 crore, and net profit was down 87.54% from Rs 25.84 crore in Q4 FY26. Operating margin stood at 4.60% in Q1 FY27 against negative 0.76% in the September 2025 quarter, which is the comparison the Orchid Pharma Q2 results print will be read against.

Q2 FY26 Base: The Comparison Orchid Pharma Q2 Results FY27 Must Beat

Orchid Pharma Ltd. reported revenue of Rs 193.52 crore and a loss of Rs 5.72 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Orchid Pharma Q2 results preview.

Because the base quarter itself was loss-making, a year-on-year percentage comparison of profit is not meaningful for Orchid Pharma. The more useful test in the Orchid Pharma Q2 results print is whether the company reports a profit at all, and how the income line of Rs 193.52 crore compares with the Rs 304.17 crore of the June 2026 quarter.

Orchid Pharma Quarterly Results Trend Over the Last Four Quarters

Quarter	Revenue (Rs Cr)	Net Profit (Rs Cr)
Q2 FY26 (Sep 2025)	193.52	(5.72)
Q3 FY26 (Dec 2025)	207.27	(12.61)
Q4 FY26 (Mar 2026)	368.33	25.84
Q1 FY27 (Jun 2026)	304.17	3.22

Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this Orchid Pharma Q2 results preview uses.

Revenue across those four quarters ranged from Rs 193.52 crore to Rs 368.33 crore, and net profit from Rs 12.61 crore loss to Rs 25.84 crore. That spread is the honest context for the Orchid Pharma Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.

Key Factors That Could Shape Orchid Pharma Q2 Results FY27

The Orchid Pharma Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Orchid Pharma has already reported.

Two Loss Quarters Were Masked by Other Income

June and September 2025 recorded operating losses of Rs 5.65 crore and Rs 1.47 crore against other income of Rs 11.57 crore and Rs 10.77 crore. The net losses of about Rs 5.7 crore each would have been substantially larger without that line.

Cephalosporin Pricing Sets the Margin

Antibiotic active ingredients are a commodity market with Chinese supply setting the reference price, so realisation moves independently of volume. A margin that swings from negative 2.15% to positive 8.19% inside a year is a price story rather than a demand one.

Depreciation Absorbs the Operating Line

It ran Rs 8.90 crore to Rs 10.95 crore in every quarter against operating profit that only twice exceeded Rs 14 crore, which is why net profit is small even in good quarters. The share trades at 3.87 times book value of Rs 254.00 with return on equity of 1.35%.

Orchid Pharma Q2 Results FY27: Share Price and Valuation Going Into the Print

Orchid Pharma share price today is Rs 1,000.20 on the NSE, down Rs 2.85 or 0.28% from the previous close of Rs 1,003.05 on 15 September 2026, ahead of the Orchid Pharma Q2 results announcement.

Metric	Value (15 September 2026)
NSE Symbol	ORCHPHARMA
Current Market Price	Rs 1,000.20
52-Week High	Rs 1,133.00
52-Week Low	Rs 480.00
Market Capitalisation	Rs 5,991 crore
PE Ratio	476.28
PB Ratio	3.94
EPS (TTM)	Rs 2.10
Book Value per Share	Rs 254.00
Debt to Equity	0.28
Return on Equity	1.35%
50-Day Moving Average	Rs 1002.63
200-Day Moving Average	Rs 789.25
RSI (14)	44.34

The stock trades below its 50-day average of Rs 1002.63 but above its 200-day average of Rs 789.25, with a 14-day RSI of 44.34. None of this is a view on where the shares go once the Orchid Pharma Q2 results are announced, and no price target is offered here.

Download the Univest iOS App or Univest Android App to track Orchid Pharma Ltd. live price and quarterly earnings updates.

What Investors Should Watch When Orchid Pharma Q2 Results Are Announced

Four lines carry most of the information in a company of this size, and reading them in order keeps the Orchid Pharma Q2 results print in proportion.

1. Revenue against the Rs 193.52 crore reported in the September 2025 base quarter
2. Net profit against a loss of Rs 5.72 crore in that same quarter
3. Operating margin against 4.60% in Q1 FY27
4. Any exceptional item, provision or one-off gain disclosed alongside the numbers

A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Orchid Pharma Q2 results announcement should be read together with the notes to the results rather than the headline alone.

Conclusion on Orchid Pharma Q2 Results FY27

The Orchid Pharma Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Orchid Pharma Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.

On that basis the Orchid Pharma Q2 results FY27 print faces a base of Rs 193.52 crore in revenue and a loss of Rs 5.72 crore, with the most recent quarter having delivered Rs 304.17 crore and a profit of Rs 3.22 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Orchid Pharma, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.

FAQs on Orchid Pharma Q2 Results FY27

What is the Orchid Pharma Q2 results date for FY27?

Ans. The Orchid Pharma Q2 results date for FY27 is not confirmed. Orchid Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE as of 15 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.

What quarter do the Orchid Pharma Q2 results 2026 cover?

Ans. The Orchid Pharma Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Orchid Pharma Ltd. reports revenue, operating profit and net profit for that period, and the Orchid Pharma Q2 results filing also carries the notes to the accounts.

What were the Orchid Pharma Q1 FY27 results?

Ans. Orchid Pharma Ltd. reported revenue of Rs 304.17 crore in Q1 FY27 and a profit of Rs 3.22 crore at the net level. Revenue was up 15.57% versus Q1 FY26 and net profit was a swing from a loss of Rs 5.69 crore in Q1 FY26 to a profit of Rs 3.22 crore.

What were Orchid Pharma Q2 FY26 results in the September 2025 quarter?

Ans. Orchid Pharma Ltd. reported revenue of Rs 193.52 crore and a loss of Rs 5.72 crore in Q2 FY26. Operating margin was negative 0.76%. Those figures form the base for the Orchid Pharma Q2 results FY27 comparison.

What are the main Orchid Pharma Q2 results expectations this quarter?

Ans. No verified analyst estimate is publicly available. The Orchid Pharma Q2 results expectations centre on revenue against the Rs 193.52 crore base, net profit against a loss of Rs 5.72 crore, operating margin against 4.60% in Q1 FY27, and any exceptional item disclosed with the numbers.

What is Orchid Pharma share price today ahead of the Q2 earnings?

Ans. Orchid Pharma share price is Rs 1,000.20 on the NSE as of 15 September 2026, down 0.28% from Rs 1,003.05. The stock is about 11.7% below its 52-week high of Rs 1,133.00 and 108.4% above its 52-week low of Rs 480.00, at a market capitalisation of Rs 5,991 crore.

Is Orchid Pharma a good stock to buy before the Q2 results?

Ans. This article does not offer a buy, sell or hold recommendation on Orchid Pharma Ltd. The stock trades at a price-to-book ratio of 3.94 with a return on equity of 1.35%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.